Retirement Guys Formula LLC grew its stake in Galectin Therapeutics Inc. (NASDAQ:GALT – Free Report) by 87.0% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 21,500 shares of the company’s stock after buying an additional 10,000 shares during the quarter. Retirement Guys Formula LLC’s […]
Retirement Guys Formula LLC grew its stake in shares of Galectin Therapeutics Inc. (NASDAQ:GALT – Free Report) by 87.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 21,500 shares of the company’s stock after buying an additional 10,000 shares […]
Galectin Therapeutics (NASDAQ:GALT – Get Free Report)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a research note issued on Monday, Benzinga reports. They currently have a $11.00 price objective on the stock. HC Wainwright’s target price would indicate a potential upside of 350.82% from the company’s current price. Separately, […]
29.03.2024 - NORCROSS, Ga., March 29, 2024 (GLOBE NEWSWIRE) - Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended .
Galectin Therapeutics, Inc. , the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended December 31,.